Generation Bio Company News - GBIO | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Generation Bio Company (GBIO)
Generation Bio Company (GBIO) News

Generation Bio Company (GBIO)

1.27

-0.01

(-0.78%)

Closed 12 December 8:00AM

Delayed by 15 minutes

1.27

0.00

( 0.00% )

Pre Market: 11:00PM

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress

New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Generation Bio to Present at the 2024 Cantor Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

1
Next

PonkenPlonken

PonkenPlonken 1 month ago

If things arent all too dire at MRNA, double down on GBIO should be coming soon

Monksdream

Monksdream 3 months ago

Monksdream

Monksdream 5 months ago

glenn1919

glenn1919 9 months ago

GBIO...................................https://stockcharts.com/h-sc/ui?s=GBIO&p=W&b=5&g=0&id=p86431144783

willlbone

willlbone 1 year ago

Welcome to Oct 2023. Buy the dip

crudeoil24

crudeoil24 5 years ago

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering price of $19.00 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,578,947 additional shares of common stock at the initial public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.
Generation Bio has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading on Friday, June 12, 2020 under the ticker symbol “GBIO.” The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Generation Bio, are expected to be approximately $200 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on Tuesday, June 16, 2020, subject to customary closing conditions.

crudeoil24

crudeoil24 5 years ago

Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The Company is a preclinical stage company and have not identified a product candidate.

Cole Real Estate

Bmo International Equity...

Brookfield BRP Holdings ...

Edinburgh Investment

Bmo Risk Reduction Fixed...

Bmo Sia Focused Canadian...

Bofa Finance Llc Issuer ...

Global Partner Acqusitio...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions